NGS in Cancer Genetics: The Challenge of Distinguishing Clonal Hematopoiesis from Tumor-specific Mutations

Check out this On-Demand Spotlight interview titled "Clonal Hematopoiesis and Cancer Genetics: How Are They Linked, How Is Research Evolving?,"

One of the more intriguing developments in cancer research in recent years is the growing understanding of clonal hematopoiesis, a phenomenon where blood cells expand from a single clone due to genetic mutations. Clonal hematopoiesis increases in prevalence with age and can precede hematologic malignancies. This area of study not only provides insights into the aging process, but also has significant implications for cancer diagnostics, treatment strategies, and new therapy development.

This Xtalks Spotlight edition delves deeper into the intricate relationship between clonal hematopoiesis and cancer genetics by speaking with Dr. Karina Eterovic, a leading expert in precision oncology and the R&D Director of Oncology Diagnostics at Eurofins Viracor BioPharma Services.

Dr. Eterovic brings much knowledge and experience to the table, having led the development of a new Oncology Diagnostic program at Eurofins Viracor that integrates the latest genomic profiling techniques.